Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials
This study has been completed.
Sponsor:
Amgen
Collaborator:
Immunex Corporation
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT00357903
First received: July 26, 2006
Last updated: May 10, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This study was designed to provide all adult and pediatric arthritis patients (placebo and etanercept(TNFR:Fc) treated) who have participated in clinical trials with etanercept (TNFR:Fc) the opportunity to receive continued treatment with etanercept (TNFR:Fc). The primary objective of this study is to examine safety parameters.
| Condition | Intervention | Phase |
|---|---|---|
|
Rheumatoid Arthritis |
Biological: Etanercept |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Open-Label Extension Treatment With Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) for Participating Patients in Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) Clinical Trials |
Resource links provided by NLM:
Further study details as provided by Amgen:
Primary Outcome Measures:
- Total Exposure to Etanercept With Gaps [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]Total participant exposure to etanercept (Enbrel) with gaps
- Total Exposure Adjusted Rate of Malignancies [ Time Frame: Up to 10 years ] [ Designated as safety issue: Yes ]Exposure-adjusted rate of malignancies, excluding nonmelanoma skin cancers, occurring on study within 30 days of the last dose of etanercept
- Total Exposure Adjusted Rate of Deaths [ Time Frame: Up to 10 years ] [ Designated as safety issue: Yes ]Rate of deaths within 30 days of the last dose of etanercept, adjusted for total exposure to etanercept
- Total Exposure Adjusted Rate of Serious Infectious Events [ Time Frame: Up to 10 years ] [ Designated as safety issue: Yes ]Exposure-adjusted rate of serious infectious events (associated with hospitalization or IV antibiotics) occurring on study within 30 days of the last dose of etanercept
- Total Exposure Adjusted Rate of Lymphomas [ Time Frame: Up to 10 years ] [ Designated as safety issue: Yes ]Rate of lymphomas occurring on study within 30 days of the last dose of etanercept, adjusted for total exposure to etanercept
- Malignancy [ Time Frame: Up to 10 years ] [ Designated as safety issue: Yes ]Occurrence of one or more malignancies on study within 30 days of the last dose of etanercept
- Lymphoma [ Time Frame: Up to 10 years ] [ Designated as safety issue: Yes ]Occurrence of one or more lymphomas on study within 30 days of the last dose of etanercept
- Serious Infectious Event [ Time Frame: Up to 10 years ] [ Designated as safety issue: Yes ]Occurrence of one or more serious infectious events within the participant on study within 30 days of the last dose of study medication. A serious infectious event is a serious adverse event that is infectious.
- Death [ Time Frame: Up to 10 years ] [ Designated as safety issue: Yes ]Occurrence of death on study within 30 days of the last dose of etanercept
- Total Exposure Adjusted Rate of Serious Adverse Events [ Time Frame: Up to 10 years ] [ Designated as safety issue: Yes ]Rate of serious adverse events adjusted to total exposure to etanercept (events / exposure * 100)
Secondary Outcome Measures:
- Dosing Period [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]Duration of etanercept dosing
- Tender Joint Count [ Time Frame: Month 12 ] [ Designated as safety issue: No ]Number of tender joints, as assessed by the investigator using criteria based on pressure and joint manipulation
- Swollen Joint Count [ Time Frame: Month 12 ] [ Designated as safety issue: No ]Number of swollen joints
- Health Assessment Questionnaire Disability Index [ Time Frame: Month 12 ] [ Designated as safety issue: No ]Health Assessment Questionnaire Disability Index (HAQ DI). This index is a weighted average of 24 items, each scored 0 (no difficulty) to 3 (unable to function).
- Childhood Health Assessment Questionnaire [ Time Frame: Month 12 ] [ Designated as safety issue: No ]Childhood Health Assessment Questionnaire (CHAQ) disability index, having a range of 0 (no difficulty) to 3 (unable to do).
- C-Reactive Protein [ Time Frame: Month 12 ] [ Designated as safety issue: No ]C-reactive protein at month 12
- ACR20 at Month 3 in Adults [ Time Frame: Baseline and month 3 ] [ Designated as safety issue: No ]American College of Rheumatology (ACR) 20, defined as a 20% improvement in both tender and swollen joints (78 joints) and a 20% improvement in 3 of 5 items (including physician and patient global assessments), in adults
- JRA DOI 30 at Month 3 in Juveniles [ Time Frame: Baseline and month 3 ] [ Designated as safety issue: No ]Juvenile Rheumatoid Arthritis Definition of Improvement 30 (JRA DOI 30), defined as a 30% improvement from baseline in 3 of 6 items (including Childhood Health Assessment Questionnaire, disease severity, overall well-being, and erythrocyte sedimentation rate) and a worsening of >30% in at most one of the remaining items.
- Standardized Incidence Rate for All SEER Cancers [ Time Frame: up to 10 years ] [ Designated as safety issue: No ]Standardized incidence rate for all cancers tracked by the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) system.
| Enrollment: | 639 |
| Study Start Date: | April 1997 |
| Study Completion Date: | April 2009 |
| Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1
N/A
|
Biological: Etanercept
Adult Rheumatoid Arthritis (RA) patients on etanercept (TNFR:Fc) with well controlled arthritic symptoms will continue on the etanercept (TNFR:Fc) dose administered in their original protocol of enrollment. All other adults will receive 50 mg per week as two 25 mg subcutaneous (SC) injections at separate sites, either on the same day or 3 or 4 days apart. Pediatric patients ages 4 to 17 years will receive a 0.8 mg/kg per week dose (up to a maximum of 50 mg per week).
|
Eligibility| Ages Eligible for Study: | 4 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Previous enrollment in Immunex protocols
- No clinically significant adverse events thought to be due to etanercept (TNFR:Fc) during previous treatment.
- Negative serum pregnancy test not more than 14 days before the first dose of study drug in females of childbearing potential.
- No more than one NSAID at a dose not greater than the maximum recommended dose and stable for at least two weeks prior to administration of etanercept (TNFR:Fc). Exclusion Criteria: - Previous receipt of TNFR:Fc (p55), antibody to TNF, anti-CD4 antibody, or diphtheria IL-2 fusion protein.
- Receipt of investigational drugs or biologics (other than TNFR:Fc [p75]) within 1 month prior to the first dose of etanercept (TNFR:Fc) in this study.
- Receipt of DMARDs or methotrexate (except patients from 16.0014) within two weeks prior to the first dose of etanercept (TNFR:Fc) in this study.
- Receipt of cyclophosphamide within six months prior to the first dose of (etanercept (TNFR:Fc) in this study.
- Receipt of cyclosporin within two weeks prior to the first dose of etanercept (TNFR:Fc) in this study.
Contacts and Locations More Information
Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Amgen |
| ClinicalTrials.gov Identifier: | NCT00357903 History of Changes |
| Other Study ID Numbers: | 20021618, 16.0018 |
| Study First Received: | July 26, 2006 |
| Results First Received: | November 4, 2010 |
| Last Updated: | May 10, 2013 |
| Health Authority: | Canada: Health Canada United States: Food and Drug Administration United States: Western Institutional Review Board |
Keywords provided by Amgen:
|
Rheumatoid Arthritis, Etanercept, Long-term Safety, Enbrel |
Additional relevant MeSH terms:
|
Arthritis Arthritis, Rheumatoid Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases TNFR-Fc fusion protein Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics |
Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Gastrointestinal Agents Immunologic Factors Immunosuppressive Agents Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 22, 2013